PYC Therapeutics Advances Clinical Trial for PKD Treatment

The latest update is out from PYC Therapeutics Limited ( (AU:PYC) ).

PYC Therapeutics Limited has received approval to escalate dosing in its clinical trial for PYC-003, a drug candidate for Polycystic Kidney Disease (PKD). The Safety Review Committee has approved the increase in dosage for the second cohort of healthy volunteers, with plans to initiate dosing in PKD patients upon successful review of safety data. This progression marks a significant step in PYC’s clinical trial process, potentially leading to a Phase 2/3 trial aimed at supporting a New Drug Application for PYC-003.

The most recent analyst rating on (AU:PYC) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.

More about PYC Therapeutics Limited

PYC Therapeutics Limited is a precision medicine company focused on developing treatments for genetic diseases that currently have no available options. The company is engaged in three clinical-stage drug development programs, including PYC-003, which targets the underlying cause of Polycystic Kidney Disease (PKD).

Average Trading Volume: 498,976

Technical Sentiment Signal: Buy

Current Market Cap: A$699.9M

For a thorough assessment of PYC stock, go to TipRanks’ Stock Analysis page.